How should I manage a patient with glucosuria (urine glucose 15 mmol/L) and microscopic hematuria (~80 RBC/µL, 2+ blood) on urinalysis, with otherwise normal findings?

Glucosuria with Microscopic Hematuria: Evaluation and Management

This urinalysis shows glucosuria (15 mmol/L) with microscopic hematuria (~80 RBC/µL, 2+ blood) that requires immediate confirmation by microscopic examination and risk-stratified evaluation for both metabolic and urologic causes.

Immediate Diagnostic Confirmation

Confirm true microscopic hematuria by obtaining a fresh microscopic urinalysis on a properly collected clean-catch midstream specimen showing ≥3 red blood cells per high-power field (RBC/HPF) before proceeding with any urologic work-up. 1 Dipstick testing alone has only 65–99% specificity and may yield false-positive results from myoglobin, hemoglobin, or contaminants. 1

• The dipstick shows "blo 80 ery/ul, blood 2+" which suggests hematuria, but microscopic confirmation is mandatory before initiating imaging or cystoscopy 1
• If microscopy confirms <3 RBC/HPF, document as normal and discontinue hematuria work-up 1
• If microscopy confirms ≥3 RBC/HPF, proceed with risk stratification for urologic evaluation 1

Evaluate the Glucosuria First

Measure serum glucose immediately to determine if this represents undiagnosed diabetes mellitus, as urine glucose appears when blood glucose exceeds the renal threshold of approximately 10 mmol/L (180 mg/dL). 2

• Urine glucose of 15 mmol/L is markedly elevated and strongly suggests hyperglycemia 2
• Semiquantitative urine glucose testing does not accurately reflect plasma glucose concentration and cannot distinguish between euglycemia and hypoglycemia 2
• If serum glucose is elevated, obtain hemoglobin A1c to assess for diabetes mellitus 3
• If serum glucose is normal, consider familial renal glucosuria (FRG), a benign condition caused by SGLT2 mutations 4

Common Pitfall: Alcohol-Induced Transient Abnormalities

Heavy alcohol consumption can induce transient proteinuria, hematuria, and glucosuria that resolve with abstinence. 5 If the patient has recent heavy alcohol use, repeat urinalysis after 1–2 weeks of abstinence may clarify whether abnormalities are persistent. 5

Risk Stratification for Hematuria (If Confirmed ≥3 RBC/HPF)

Use the 2025 AUA/SUFU risk stratification system to determine the extent of urologic evaluation required. 2

High-Risk Features (require cystoscopy + CT urography):

• Age ≥60 years (men or women) 2
• Smoking history >30 pack-years 2

• 25 RBC/HPF on microscopy 2

• History of gross hematuria (even if self-limited) 2
• Occupational exposure to benzenes, aromatic amines, or chemicals/dyes 2
• Irritative voiding symptoms without documented infection 2

Intermediate-Risk Features (shared decision-making):

• Men age 40–59 years 2
• Women age ≥60 years (without other high-risk features) 2
• Smoking history 10–30 pack-years 2
• 11–25 RBC/HPF 2

Low-Risk Features (may defer extensive imaging):

• Men <40 years 2
• Women <60 years 2
• Never smoker or <10 pack-years 2
• 3–10 RBC/HPF 2

Distinguish Glomerular from Urologic Sources

Examine urinary sediment for dysmorphic RBCs (>80% suggests glomerular) and red cell casts (pathognomonic for glomerular disease). 1

Glomerular Indicators (require nephrology referral):

• Dysmorphic RBCs >80% on microscopy 1
• Red blood cell casts 1
• Significant proteinuria (spot protein-to-creatinine ratio >0.5 g/g) 1
• Elevated serum creatinine or declining eGFR 1
• Tea-colored or cola-colored urine 1
• Hypertension accompanying hematuria 1

Urologic Indicators (proceed with urologic evaluation):

• Normal-shaped RBCs with minimal proteinuria 1
• Negative protein on dipstick (as in this case) 1
• Age and risk factors for malignancy 1

The absence of proteinuria in this urinalysis (neg protein) suggests a non-glomerular source, making urologic evaluation the priority. 1

Complete Urologic Evaluation (If High-Risk or Intermediate-Risk)

Upper Tract Imaging:

Multiphasic CT urography (unenhanced, nephrographic, excretory phases) is the preferred imaging modality, providing 96% sensitivity and 99% specificity for renal cell carcinoma, transitional cell carcinoma, and urolithiasis. 1

• When CT is contraindicated (severe renal insufficiency or contrast allergy), MR urography or renal ultrasound with retrograde pyelography are alternatives 1
• Renal ultrasound alone is insufficient for comprehensive upper tract evaluation 1

Lower Tract Evaluation:

Flexible cystoscopy is mandatory for all patients ≥40 years with confirmed microscopic hematuria or any patient with gross hematuria. 1

• Bladder cancer accounts for 30–40% of gross hematuria cases and 2.6–4% of microscopic hematuria cases 1
• Flexible cystoscopy provides equivalent or superior diagnostic accuracy to rigid cystoscopy with less discomfort 1

Laboratory Evaluation:

• Serum creatinine and eGFR to assess renal function 1
• Spot urine protein-to-creatinine ratio 1
• Urine culture if infection suspected (before antibiotics) 1
• Voided urine cytology in high-risk patients (age >60, smoking >30 pack-years, occupational exposures) 1

Follow-Up Protocol (If Initial Work-Up Negative)

Repeat urinalysis at 6,12,24, and 36 months with blood pressure monitoring at each visit. 1

• After two consecutive negative annual urinalyses, further testing is unnecessary 1
• Immediate re-evaluation is required if: gross hematuria develops, microscopic hematuria markedly increases, new urologic symptoms appear, or hypertension/proteinuria/glomerular bleeding emerges 1
• High-risk patients with persistent hematuria should consider repeat cystoscopy and imaging within 3–5 years 1

Critical Pitfalls to Avoid

• Never ignore hematuria based solely on the presence of glucosuria—the two findings require separate evaluation 1
• Do not attribute hematuria to diabetes or metabolic causes without completing urologic work-up in patients with risk factors 1
• Do not rely solely on dipstick results—microscopic confirmation of ≥3 RBC/HPF is mandatory 1
• Gross hematuria carries a 30–40% malignancy risk and requires urgent urologic referral even if self-limited 1, 6
• Anticoagulation or antiplatelet therapy does not cause hematuria—these medications may unmask underlying pathology but evaluation must proceed 1